B. Riley Securities maintains Buy rating on OptimizeRx, $11 price targetTradingView·2 days ago, 03:45 PMOPRX+0.48%
OptimizeRx integrates with Trade Desk OpenPath to offer authenticated EHR ad inventoryPUBT·Sep 22 at 12:08 PMTTD-0.58%OPRX+0.48%
OptimizeRx expands Natural Language Audience Builder to add DTC targeting workflowPUBT·Sep 14 at 12:06 PMOPRX+0.48%
OptimizeRx management participates in Lake Street Capital Best Ideas Growth ConferencePUBT·Sep 8 at 11:32 AMOPRX+0.48%
OptimizeRx appoints former J&J commercial data science chief Troy Sarich as adviserPUBT·Sep 2 at 11:31 AMOPRX+0.48%
OptimizeRx (OPRX) Fiscal Q2 2026 Earnings Call: Guidance Reaffirmed as Revenue Falls 30%TradingKey·Aug 14 at 08:32 AMOPRX+0.48%
OptimizeRx Q2 GAAP net loss narrows to $0.7 million; revenue drops 30% to $20.5 million year over yearPUBT·Aug 12 at 08:03 PMOPRX+0.48%
